德谷门冬双胰岛素是由新一代超长效基础胰岛素类似物（德谷胰岛素）联合餐时胰岛素类似物（门冬胰岛素）组成的新型胰岛素类似物复方制剂，可以每天使用一或两次，同时提供基础和餐时胰岛素需求，与目前的胰岛素制剂相比具有较低的低血糖风险。综述了德谷门冬双胰岛素与预混胰岛素、基础餐时胰岛素及基础胰岛素方案比较的临床研究进展，为临床上更好地应用提供参考。

Insulin degludec/insulin aspart is a compound preparation of new type insulin consisting of a ultra-long acting basal insulin (Degludec) and a bolus insulin (Aspart).It can be used once or twice-daily,providing reliable coverage of both basal and prandial insulin requirements with a lower risk of hypoglycaemia than current insulin options.This article reviews clinical trials on comparing IDegAsp with three other currently available treatment options:premixed insulin,basal-bolus regimens and basal-only therapy,with view to providing references in clinical application.